Methimazole Is an Inhibitor of Melanin Synthesis in Cultured B16 Melanocytes  by Kasraee, Behrooz et al.
Methimazole Is an Inhibitor of Melanin Synthesis in Cultured
B16 Melanocytes
To the Editor:
Recently, we have demonstrated in vivo that topical
application of the antithyroid agent methimazole (1-
methyl-2-mercaptoimidazole: MMI) on dark brown guinea-
pig skin produces cutaneous depigmentation (Kasraee,
2002b). The DOPA incubation of the depigmented speci-
mens revealed that MMI induces morphology changes of
melanocytes in the treated skin. But unlike most depig-
menting chemicals that act as melanocytotoxins, MMI did
not cause a significant decrease in the numerical count of
melanocytes. This indicated that MMI-induced depigmen-
tation in vivo might result from the inhibition of the
melanogenesis pathway in viable melanocytes, rather than
a melanocytotoxic effect. To verify this in vitro, we
compared the depigmenting and melanocytotoxic effects
of MMI with those of kojic acid, hydroquinone, and arbutin,
on cultured B16 murine melanocytes.
B16 melanocytes were grown in DMEM/10% fetal bovine
serum (FBS) supplemented with 10 nM Cholera toxin, and
the murine BDVII keratinocytes were grown in RPMI/10%
FBS. MMI was dissolved in vehicle (propylene glycol:etha-
nol:water (5:3:2)) and was exposed to the cells at final
concentrations in medium ranging from 0 to 100 mg per mL
(0–880 mM) during four consecutive days according to the
Dooley method (Dooley et al, 1994). On the fifth day, the
melanocytes were harvested, sonicated, and centrifuged.
DMSO was added to the pellet, the suspension was
sonicated, and melanin determination was performed
spectrophotometrically at 405 nm. The results from tripli-
cate samples were analyzed as percent of control. Cell
viability was determined on the fifth day for both keratino-
cytes and melanocytes, using MTT assay (Sieuwerts et al,
1995). For melanocytes, the specificity of melanogenesis
inhibition was assessed by dividing the melanin content by
the amount of reduced MTT.
At the highest concentration examined (880 mM), MMI
was still well tolerated, as shown by the MTT assay,
although it inhibited the melanogenesis activity of B16
melanocytes by more than 50% when compared with
control (Fig 1A). The (melanin/MTT) ratio showed a
concentration-dependent decrease, indicating that the
depigmenting effect of MMI on cultured melanocytes is
a result of the inhibition of melanin synthesis and not a
melanocytotoxic effect (Fig 1B). Hydroquinone, a well-
known depigmenting agent, was shown to be efficient as
an inhibitor of melanogenesis in B16 melanocytes (Figs 2A
and 2B); however, hydroquinone was highly toxic at 10 mM
(Fig 2A), indicating that its observed depigmenting action
in vivomay be due, at least in part, to its melanocytotoxicity.
Arbutin, a phenolic compound used as a skin-lightening
Figure1
Effect of MMI on melanogenesis. MMI was added at various
concentrations on B16 melanocytes, and then melanin content and
MTTassay were performed (A). For MTT assay, 100 ml of a 5 mg per ml
MTTsolution was added to each well and the plates were incubated for
3 h at 371C. The formed MTT formazan crystals were dissolved by
adding 500 mL DMSO, and spectrophotometric assay was carried out
at 500 nm. (B) Ratio of melanin content (mg) per mmol of MTT formazan
produced, for the same number of cells.
Abbreviations: FBS, fetal bovine serum; MMI, methimazole
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agent in cosmetics, possesses a hydroquinone moiety
bound to glucose. In B16 melanocytes, it began to be
cytotoxic between 0.1 and 1 mM, while inducing a
significant decrease of melanin already at 10 mM (Fig 3);
this indicates that arbutin possesses a specific inhibiting
action on melanocytes in vitro at moderate concentrations.
Kojic acid, an inhibitor of tyrosinase and other oxidases
(Burdock et al, 2001) also used as a lightening agent
(Burdock et al, 2001), exhibited a low toxicity but an
absence of inhibition of melanogenesis in cultured melano-
cytes (Fig 4). In order to distinguish between a selective
melanocytotoxicity and a general cytotoxicity, an MTTassay
was performed with the four compounds in murine BDVII
keratinocytes. As shown in Fig 5, hydroquinone was
cytotoxic in a concentration-dependent manner, whereas
arbutin and kojic acid were non-toxic up to 100 mM, and
MMI up to 880 mM.
The depigmenting activity of MMI on guinea-pigs does
not go beyond a mild to moderate depigmentation. The
moderate depigmenting activity of MMI in vivo is in
accordance with its potency to depigment cultured mela-
nocytes in vitro.
Melanocyte peroxidase is presently believed to be
involved in several steps of the melanogenesis pathway.
These steps include the oxidation of DOPA to dopaquinone
(Bertazzo et al, 1999), the oxidative polymerization of indolic
melanin monomers to form eumelanin (d’Ischia et al, 1991),
and the oxidation of phenothiazine type intermediates in the
production of pheomelanins (Kasraee, 2002a). In melanoma
cells, pigment deposition begins to appear when perox-
idase exhibits its highest levels of activity, i.e., in stages II
and III premelanosomes (Shibata et al, 1993). On the other
hand, amelanotic melanoma cells are negative for perox-
idase activity (Shibata et al, 1993). We have recently
reported a high correlation between the melanogenesis-
inhibiting activity of chemicals and their ability to inhibit
peroxidases (Kasraee, 2002a). The inhibition of peroxidase
is a common property among most known melanogenesis
inhibitors, whether or not they inhibit tyrosinase. Steroids,
ascorbic acid, and indomethacin are examples of melano-
genesis inhibitors that do not inhibit tyrosinase but inhibit
Figure 2
Effect of hydroquinone on melanogenesis. See Fig 1 legend. The
melanin/MTT formazan ratio increases for concentrations higher than
10 mM; this is due to the very low number of cells, as revealed by the
MTT assay, but has no biological relevance.
Figure3
Effect of arbutin on melanogenesis. See Fig 1 legend.
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peroxidase activity (Kasraee, 2002a). MMI is a well-known
inhibitor of peroxidases from different sources (Balazs
et al, 1986) and therefore could interfere with the melanin
synthesis pathway at several steps.
Most known skin depigmenting chemicals act by
destroying the epidermal melanocytes. Such agents are
substrates of melanocytic enzymes such as tyrosinase and/
or peroxidase, and their metabolization by these enzymes
gives rise to the formation of intracellular cytotoxic species
that kill the pigment cells (Kasraee, 2002a). Such a cytotoxic
effect, however, is not highly specific for the melanocytes,
and other cells such as keratinocytes could also be
affected. This non-specific cytotoxicity is, most likely, the
result of autooxidation of these compounds (Passi et al,
1987) as well as their peroxidase-mediated metabolization
within such cells (Kasraee, 2002a). The non-selective cyto-
toxicity as well as the mutagenic potential of melano-
cytotoxins has recently raised serious questions of concern
regarding their continual use in the dermatologic products.
MMI has several advantages over known depigmenting
agents: (1) unlike hydroquinone that, even at very low
concentrations, shows strong cytotoxic effects towards
melanocytes and keratinocytes, MMI is non-cytotoxic up to
high concentrations; (2) unlike hydroquinone (Joseph et al,
1998) and kojic acid (Wei et al, 1991), which are known to be
mutagenic on mammalian cells, MMI has been demon-
strated to be devoid of any mutagenic effect (Akatsuka et al,
1979); (3) MMI is relatively stable and does not easily
undergo autooxidation; (4) most thiol compounds with
depigmenting ability such as mercaptoethylamines have
offensive odors, which prohibits their use in topical
products (Frenk et al, 1968); MMI, however, is an odorless
thiol; (5) Despite the equivocal in vitro results on the
melanogenesis-inhibiting effects of kojic acid and arbutin,
the skin depigmenting action of these two agents has never
been confirmed in any controlled in vivo study, whereas the
skin depigmenting effect of MMI is also confirmed in vivo
(brown guinea-pig model); and eventually (6) MMI, when
used topically, reduces the UV-induced erythema in the
human skin (Moseley et al, 1989) and therefore may
simultaneously serve as a sun protectant.
Although in our model arbutin was shown to be non-
cytotoxic and as efficient as MMI in inhibiting melanogen-
esis, arbutin is a glycoside containing a hydroquinone
moiety, and it is not excluded that epidermal cells, due
to the presence of glycosidases (Holleran et al, 1992;
Redoules et al, 1999), can hydrolyze it to deliver free
hydroquinone. Thus, it is possible that long-term use in
humans of topical arbutin could lead to deleterious side
effects due to the delivery of hydroquinone.
In conclusion, kojic acid is non-toxic but poorly effective,
as confirmed by other studies (Curto et al, 1999; Lei et al,
2002; Springer et al, 2003), hydroquinone is effective but
highly cytotoxic and mutagenic (Curto et al, 1999), arbutin is
effective in vitro but lacks the data confirming its in vivo
efficacy, and is also potentially toxic and mutagenic when
used for a long time, whereas MMI is shown to be effective
as a depigmenting agent both in vitro and in vivo, and is
non-cytotoxic and non-mutagenic. Therefore, MMI could
Figure 4
Effect of kojic acid on melanogenesis. See Fig 1 legend.
Figure5
Cytotoxicity of MMI, hydroquinone, arbutin, and kojic acid on
BDVII keratinocytes. The cytotoxicity was assessed by using the MTT
assay (see Fig 1 legend).
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serve as a lead compound for the discovery of novel safe
and efficient skin depigmenting compounds in the future.
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